Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmunicIMUX +0.53%32 3-Year EBITDA Growth Rate is 37.50% as of Mar. 2026, which is 47% above its 10-year median of 25.50. GuruFocus rates IMUX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,135 Biotechnology companies, Immunic ranks better than 75.42% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 37.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 29.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 39.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Immunic was 60.70% per year. The lowest was -52.90% per year. And the median was 25.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Immunic 3-Year EBITDA Growth Rate Related Terms
IMUX vs MDWD, WHWK, IVVD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Immunic's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunic 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunic's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Immunic's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 37.50% mean?
Immunic (IMUX) has a 3-Year EBITDA Growth Rate of 37.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Immunic and its competitors. This is 47% above median its historical median of 25.50. According to the industry distribution chart, Immunic ranks #279 out of 1135 companies in the Biotechnology industry, placing it in the top 24.6%.
Is Immunic's 3-Year EBITDA Growth Rate too high?
Immunic's current 3-Year EBITDA Growth Rate of 37.50% is 47% above median its 10-year median of 25.50. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Immunic's value of 37.50% is 151.7% above this industry median. Based on the distribution chart, Immunic ranks #279 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Immunic's 3-Year EBITDA Growth Rate compare to MDWD and WHWK?
According to the Biotechnology industry distribution chart, Immunic ranks #279 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Immunic in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Immunic's value of 37.50% is 151.7% above this benchmark. While the company's 10-year median is 25.50 vs. the industry median of 14.90, Immunic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunic's current 3-Year EBITDA Growth Rate of 37.50% is 151.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Immunic and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunic's current 3-Year EBITDA Growth Rate is 37.50%, which is 47% above median its own 10-year median of 25.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunic stock overvalued right now?
Immunic (IMUX) has a current 3-Year EBITDA Growth Rate of 37.50%. The current 3-Year EBITDA Growth Rate is 37.50%, which is 47% above median its 10-year median of 25.50 and 151.7% above the Biotechnology industry median of 14.90. Immunic's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Immunic (IMUX), the current 3-Year EBITDA Growth Rate is 37.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score
Get the complete analysis for IMUX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMUX has been successfully added to your 
